Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 55 (GAPDHP55) is annotated as a genomic pseudogene derived from the glycolytic enzyme GAPDH. Like other pseudogenes in the GAPDH family, it is a non-coding sequence created by retrotransposition of the parent mRNA, followed by disabling mutations. GAPDHP55 does not encode any functional protein, is not transcribed, and has no known biological function or role in disease. It is not considered a therapeutic or research target. The parent GAPDH gene, in contrast, encodes a multifunctional enzyme involved in glycolysis and other cellular processes, but pseudogenes like GAPDHP55 are generally genomic relics without function[1][4][5][7].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 55 (GAPDHP55).